Akari Therapeutics (NASDAQ:AKTX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTXGet Rating) in a research report released on Monday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, Alliance Global Partners began coverage on Akari Therapeutics in a report on Tuesday, November 1st. They set a buy rating and a $4.00 price objective for the company.

Akari Therapeutics Trading Up 1.3 %

Shares of NASDAQ:AKTX opened at $0.57 on Monday. The stock has a market capitalization of $42.65 million, a P/E ratio of -1.64 and a beta of 1.28. Akari Therapeutics has a 1-year low of $0.38 and a 1-year high of $1.70. The business has a 50-day moving average price of $0.55 and a two-hundred day moving average price of $0.91.

Akari Therapeutics (NASDAQ:AKTXGet Rating) last announced its quarterly earnings data on Tuesday, September 27th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter.

Hedge Funds Weigh In On Akari Therapeutics

Several institutional investors have recently modified their holdings of AKTX. LPL Financial LLC acquired a new position in shares of Akari Therapeutics during the 2nd quarter worth about $83,000. Omnia Family Wealth LLC grew its position in shares of Akari Therapeutics by 3.2% during the 3rd quarter. Omnia Family Wealth LLC now owns 782,372 shares of the biopharmaceutical company’s stock worth $493,000 after buying an additional 24,228 shares during the period. Finally, Armistice Capital LLC acquired a new position in shares of Akari Therapeutics during the 3rd quarter worth about $2,703,000. 2.83% of the stock is currently owned by institutional investors and hedge funds.

Akari Therapeutics Company Profile

(Get Rating)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid.

See Also

Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.